E2F1 and hepatocellular carcinoma: Numerous studies have reported that E2F1 expression was significant for poor prognosis in malignancies such as oesophageal carcinoma [27], hepatic cellular carcinoma (HCC) [28], pancreatic cancer [29], non-small cell lung cancer [30] and breast cancer [31].